Association of VCTE-derived liver parameters and MASLD subtypes with advanced cardiovascular-kidney-metabolic syndrome
Background and aims In cardiovascular-kidney-metabolic (CKM) syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD) is not included in its staging criteria. We aimed to evaluate the associations between vibration-controlled transient elastography (VCTE)-derived liver parameters and advanced CKM stages, and to examine whether the CKM profile differs among MASLD subtypes. Methods VCTE and cardio-metabolic assessments were conducted among individuals enrolled in the New Hong Kong Cardiovascular Risk Factor Prevalence Study (NCRISPS), an ongoing population-based cohort recruiting Chinese residents of Hong Kong SAR between 2019 and 2024. Results Among 3199 eligible participants, 37.2% had MASLD, with 34.4% having MASLD alone and 2.8% due to combined etiology. VCTE-derived controlled attenuation parameter (CAP), liver stiffness (LS), and FibroScan-AST (FAST) score each showed graded associations with advanced CKM stages (all P<0.05). Compared to participants without steatotic liver disease, those with MASLD alone (adjusted OR 1.44, 95% CI 1.07–1.94; P = 0.016) and MASLD due to combined etiology (adjusted OR 2.35, 95% CI 1.22–4.49; P = 0.010) were both associated with significantly higher odds of advanced CKM stages. Conclusions MASLD, with and without combined etiology, was associated with the presence of advanced CKM syndrome. VCTE-derived parameters including CAP, LS, and FAST score were all associated with advanced CKM stages in a graded manner and whether inclusion of these non-invasive markers improves CKM syndrome staging and classification warrants longitudinal evaluation.
Authors
- David Tak Wai Lui (ORCID: https://orcid.org/0000-0002-9813-1126)
- Yu Cho Woo (ORCID: https://orcid.org/0000-0001-9559-3467)
- Chloe Y. Y. Cheung (ORCID: https://orcid.org/0000-0002-7884-5295)
- Carol Ho-Yan Fong (ORCID: https://orcid.org/0000-0003-1579-3886)
- Aimin Xu (ORCID: https://orcid.org/0000-0002-0668-033X)
- Lung‐Yi Mak (ORCID: https://orcid.org/0000-0002-2266-3935)
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- Jean Woo (ORCID: https://orcid.org/0000-0001-7593-3081)
- Hung‐Fat Tse (ORCID: https://orcid.org/0000-0003-4665-7887)
- Jimmy Ho‐Cheung Mak (ORCID: https://orcid.org/0000-0002-3241-3809)
- K. C. B. Tan (ORCID: https://orcid.org/0000-0001-9037-0416)
- Karen S.L. Lam (ORCID: https://orcid.org/0000-0001-5757-541X)
- Bernard M.Y. Cheung (ORCID: https://orcid.org/0000-0001-9106-7363)
- Chi-Ho Lee
- Lanlan Li (ORCID: https://orcid.org/0009-0002-5529-5830)
- Tai-Hing Lam
Institutions
- Chinese University of Hong Kong (HK)
- University of Hong Kong (HK)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-11-09
- DOI
- https://doi.org/10.3389/fendo.2026.1984746
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00